Medications for Human Immunodeficiency Virus I Infection

15 results

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated for the treatment of HIV-1 infection in adults and adolescents (≥12 years, ≥35 kg) as a complete regimen, replacing current antiretroviral therapy in those who are virologically suppressed with no treatment failure history and no known resistance to cabotegravir or rilpivirine.

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • evotaz

    (atazanavir and cobicistat)
    E.R. Squibb & Sons, L.L.C.
    EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

  • fuzeon

    (Enfuvirtide)
    Genentech, Inc.
    FUZEON® is indicated for the treatment of HIV-1 infection in treatment-experienced patients who show evidence of ongoing HIV-1 replication despite receiving antiretroviral therapy, in combination with other antiretroviral agents.

  • pifeltro

    (doravirine)
    Merck Sharp & Dohme LLC
    PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    Janssen Products LP
    PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    A-S Medication Solutions
    PREZCOBIX is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥40 kg), either treatment-naïve or experienced, when used with other antiretroviral agents and in the absence of specific darunavir resistance-associated substitutions.

  • prezista

    (darunavir)
    Janssen Products LP
    PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 years and older.

  • prezista

    (darunavir)
    Physicians Total Care, Inc.
    PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in both adult and pediatric patients aged 3 years and older. This is supported by clinical trial data assessing HIV-1 RNA levels and CD4+ cell counts.